We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Co-led by new investors, Vesalius BioCapital III and BioMedPartners, with participation from all existing investors Funds to be used to advance innovative pipeline based on Topas Particle Conjugates t... Highly accomplished biotech executive with nearly two decades of industry leadership experience Topas is advancing its pipeline based on its Topas Particle Conjugates technology platform, with lead pr...
Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing
Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer